ClinicalTrials.gg
RecruitingNCT07547215TRAQTIONUpdated Jun 15, 2026

Post-Market Clinical Study Using TRAQ™ for Minimally Invasive Posterior Sacroiliac Joint Fusion

An observational study in Sacroiliac Joint Dysfunction and Sacroiliac Joint Pain, sponsored by PainTEQ, LLC. Recruiting at 1 site in United States. Open to participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-06-15.

Sponsored by PainTEQ, LLC · Observational

How we know

From the registry’s dates

  • Started May 2026; still recruiting 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
100
Ages
21 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 106 studies in Arthralgia with a site in United States — 17 open to participants now, 23 under way, 4 of them phase 3. Arthralgia · United States.

Planned enrollment
12th of 18
100 · median 144
Started
2026
with 7 others
Observational
18 of 106
2 open now
Primary completion
2027-07
later than 11 of 22 live
Registered
101st of 106
by date

Among the 106 studies in Arthralgia with a site in United States, this one is the 12th largest by planned enrollment of the 18 observational ones that give a count, is one of 8 that started in 2026, is one of 18 observational ones, reaches primary completion later than 11 of the 22 other live ones, and was the 101st registered.

Arthralgia

277 studies on the registry are indexed under Arthralgia; 54 are open to participants now.

Browse Arthralgia studies →

Open to participants now

17 of the 106 studies in Arthralgia with a site in United States are open now. Recruiting first, the newest first:

11 more — sign in →

All 17 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 35 Arthralgia studies recruiting now, 18 (51%) set no upper age limit and 16 (46%) stop at 75 or younger; 1 takes children under 18; 9 take healthy volunteers.

This study: 21 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 106 studies in Arthralgia with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the real-world performance, safety and efficacy of the TRAQ System.

03

Conditions studied

  • Sacroiliac Joint Dysfunction
  • Sacroiliac Joint Pain

Browse trials for

04

Who can participate

Ages eligible
21 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects with chronic, SIJ pain will be screened for participation in this study. Subjects who provide informed consent and meet the study eligibility criteria will be enrolled and will undergo an implant procedure. Subjects will be followed up at 3-, 6-, 12-, 18-, and 24-months following the implant.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

To be eligible to participate in this study, a subject must meet all the following criteria, as determined by the Investigator:

  1. Age and (BMI)

    1. Adult patients aged ≥ 21 years at screening.
    2. BMI ≤ 40.
  2. Chronic SIJ Related Pain

    1. Has experienced low back and/or buttock pain for at least 6 months that has been inadequately responsive to non surgical management.
    2. Has experienced nonradicular pain that is maximal below the L5 vertebrae, localized over the posterior SIJ, and consistent with SIJ pain.
  3. Diagnosis of SIJ Dysfunction

    a. Has a diagnosis of SIJ dysfunction (degenerative sacroiliitis or SIJ disruption) based on ALL of the following: i. A positive Fortin's finger test; and ii. Pain elicited on at least three (3) of five (5) SIJ specific physical examination maneuvers (FABER test, Gaenslen's test, Distraction, Thigh Thrust, Compression); and iii. At least 75% reduction in pain, with associated improvement in previously painful maneuvers, for the expected duration of action following two (2) image guided, contrast enhanced intra articular diagnostic SIJ injections, performed on separate visits using anesthetics with different durations of action; and iv. Completion of at least one (1) therapeutic intra articular SIJ injection (e.g., injection) within the past 12 months.

  4. Baseline Disability and Pain Severity

    a. Baseline Oswestry Disability Index (ODI) score ≥30%; and b. Baseline SI joint pain score of ≥60 mm on a 100 mm Visual Analog Scale (VAS).

  5. Treatment Decision a. The treating physician has independently determined that the TRAQ procedure is an appropriate treatment option for the subject's SIJ dysfunction in the course of routine clinical care, and the subject has agreed to undergo this treatment.
  6. and Compliance

    1. Is willing and capable of providing written informed consent; and
    2. Is willing and able to comply with all study related requirements, procedures, and follow up visits.

Exclusion criteria

Exclusion Criteria:

Subjects must meet none of the following criteria to be eligible for participation in this study, as determined by the Investigator:

  1. Pain Source Uncertainty

    a. Inability to confirm, in the Investigator's clinical judgment, that the subject's primary pain generator is the sacroiliac joint.

  2. Alternative Primary Spine Pathology

    a. Presence of severe low back pain attributable to other spinal pathology, including but not limited to lumbar disc degeneration, lumbar disc herniation, lumbar spondylolisthesis, lumbar spinal stenosis, lumbar facet degeneration, or lumbar vertebral body fracture.

  3. Other Sacroiliac Pathology a. Presence of known sacroiliac joint pathology other than degenerative SIJ dysfunction, including inflammatory sacroiliitis (e.g., ankylosing spondylitis or other HLA associated spondyloarthropathies), tumor, infection, acute fracture, or crystal arthropathy.
  4. Non SIJ Pain Syndromes

    a. History of coccydynia or prior coccygectomy, endometriosis, cluneal neuralgia, or pudendal neuralgia.

  5. Recent Sacral Interventions

    a. Prior sacral radiofrequency ablation performed within 6 months prior to enrollment.

  6. Recent Pelvic Trauma

    a. History of major pelvic trauma within 12 months prior to enrollment.

  7. Severe Osteoporosis

    a. Prior diagnosis or suspicion of severe osteoporosis, defined as a prior bone mineral density T score of \< -2.5 or a history of osteoporotic fracture.

  8. Medications Affecting Bone or Soft Tissue Healing

    a. Current use of medications known to adversely affect bone quality or soft tissue healing, as determined by the Investigator.

  9. Anatomic Constraints

    a. Anatomic anomalies or defects that, in the Investigator's opinion, would preclude safe or biomechanically appropriate device placement.

  10. Systemic Inflammatory or Rheumatologic Disease

    a. Presence of a chronic inflammatory rheumatologic condition, such as rheumatoid arthritis.

  11. Centralized Pain Syndromes

    a. Current diagnosis of fibromyalgia.

  12. Infection Risk

    a. Evidence of current local or systemic infection that would increase surgical risk.

  13. High-Dose Opioid Therapy (≥90 MME/day)

    a. Current use of systemic opioid analgesics at Screening/Baseline with an average daily dose ≥90 morphine milligram equivalents (MME/day), based on medication reconciliation (prescription records and subject report) and standard MME conversion factors.

  14. Current Nicotine Use (Self-Reported)

    a. Self-reported use of any nicotine-containing products (including smoking, vaping/e-cigarettes, cigars, pipes, smokeless tobacco, nicotine pouches, and nicotine replacement products) within 6 weeks prior to Screening/Baseline.

  15. Secondary Gain or Litigation

    a. Currently receiving or actively seeking workers' compensation or disability benefits or involved in injury related litigation.

  16. Pregnancy

    a. Currently pregnant or planning to become pregnant within two (2) years following enrollment, as self reported.

  17. Vulnerable Populations

    a. Individuals who are prisoners or wards of the state.

  18. Substance Abuse

    a. Known or suspected active drug or alcohol abuse, including opioid misuse.

  19. Psychiatric Conditions

    a. Diagnosed psychiatric disorder (e.g., schizophrenia, major depressive disorder, personality disorder) that, in the Investigator's judgment, could interfere with study participation.

  20. Concurrent Interventional Research

    a. Current participation in another clinical trial.

  21. Neurologic Conditions Affecting Rehabilitation

    a. Presence of a significant neurologic disorder that would interfere with participation in physical therapy or post procedural rehabilitation.

  22. Other Confounding Medical Conditions a. Any other medical condition or pain condition not intended to be treated in this study that, in the Investigator's judgment, could interfere with study procedures, accurate pain reporting, or interpretation of study endpoints.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
100 participants (estimated)
Patient registry
No

Interventions

  • OtherBone Allograft

    The PainTEQ TRAQ™ Posterior SI Joint Implant is processed human bone tissue that has been precision milled from cortical and cancellous bone. The allograft pierces the SI joint cortices and provides a scaffold around which new bone can grow.

06

What researchers measure

Primary outcomes

  1. Composite safety and efficacy endpoint

    Composite Success Responder Rate at Month 6 Unit of Measure: Percentage of participants Description: The primary endpoint is a single binary (Yes/No) composite responder classification per subject at Month 6. A subject is classified as a composite success responder ONLY if ALL three of the following criteria are met: 1. Pain Improvement: Reduction in SIJ pain VAS score of ≥20 mm from baseline to Month 6 (VAS measured on 0-100 mm scale). 2. Safety: Absence of any device-related or procedure-related SAEs through Month 6 (Day 180). 3. Surgical Reintervention: No surgical reintervention for SIJ fusion through Month 6 (Day 180), including device removal (complete or partial), device revision or replacement, or reoperation at the index SIJ. Subjects meeting all three components are classified as responders; the outcome is reported as the percentage (%) of participants classified as responders.

    Time frame: Month 6

Secondary outcomes

  1. Visual Analog Scale (VAS)

    Change from baseline in VAS score (measured on 0-100 mm scale) and proportion achieving VAS MCID ≥ 20 mm.

    Time frame: Months 3, 6, 12, 18, 24.

  2. Oswestry Disability Index (ODI)

    Change from baseline in ODI and proportion achieving ODI MCID ≥ 15 points.

    Time frame: Months 3, 6, 12, 18, 24

  3. Patient-Reported Outcomes Measurement Information System (PROMIS-29+2)

    Change in T-scores from baseline

    Time frame: Months 3, 6, 12, 18, 24

  4. EuroQol 5-Dimension 5-Level (EQ-5D-5L) questionnaire

    Change in EQ-5D-5L index scores from baseline

    Time frame: Months 3, 6, 12, 18, 24

  5. Patient Global Impression of Change (PGIC)

    PGIC categorical distribution

    Time frame: Months 3, 6, 12, 18, 24

  6. Medication use

    Medication use (including daily MME for opioids) per visit

    Time frame: 3, 6, 12, 18, 24

  7. Healthcare Resource Utilization (HCRU)

    HCRU per visit

    Time frame: Months 3, 6, 12, 18, 24

07

Study locations

1 of 1 sites recruiting
  • Pain Institute of Southern Arizona
    Tucson, Arizona 85712, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No — Sponsored Study.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2026 (actual). Primary completion is estimated for Jul 2027, 14 months after the start.

Of 21 observational studies under Arthralgia, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 56. This study's planned 14 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 6, 2026
First posted
Apr 23, 2026
StartActual
May 27, 2026
Primary completionEst.
Jul 2027
CompletionEst.
Dec 2028
Last update
Jun 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07547215
Lead sponsor
PainTEQ, LLC
Responsible party
Sponsor
First posted
Apr 23, 2026
Start date
May 27, 2026
Primary completion
Jul 2027 (estimated)
Completion
Dec 2028 (estimated)
Last update
Jun 15, 2026

Study contacts

Lalit Venkatesan, PhD
Contact
lalit.venkatesan@painteq.com
18552487246

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion